News Details
EU Publishes 22nd ATP to CLP Regulation Effective May 2026
On 30 September 2024, the European Commission published the 22nd Adaptation to Technical Progress (ATP) under Regulation (EC) No 1272/2008 (CLP). The 22nd ATP was adopted on 19 June 2024 and published in the Official Journal of the European Union and amend Table 3 of Part 3 of Annex VI to the Classification, Labelling and Packaging (CLP) Regulation by introducing 27 new harmonised classifications, modifying 16 preexisting entries and deleting 7 harmonised classifications. The amendments will come into effect on 1 May 2026.
Compliance Deadlines for 22nd ATP
The new classifications enter into force on 20 October 2024 and will apply from 1 May 2026, giving suppliers sufficient time to adjust their labelling and packaging in line with the new rules. However, suppliers may voluntarily adopt the updated classifications before this date to ensure compliance and to better protect public health and the environment.
New Harmonised Classifications in 22nd ATP
The table below lists the 27 new harmonised classifications added to Part 3, Table 3 of Annex VI to the CLP Regulation. The 16 modified entries can be found here.
|
Index No |
Chemical Name |
CAS No |
Hazard Statement Codes |
|
005-022-00-4 |
Perboric acid, sodium salt |
11138-47-9 |
H272 H360FD H331 H302 H335 H318 |
|
Perboric acid, sodium salt, monohydrate |
12040-72-1
|
||
|
Perboric acid (HBO(O2)), sodium salt, monohydrate |
10332-33-9
|
||
|
Sodium peroxoborate |
- |
||
|
Sodium perborate |
15120-21-5 |
||
|
005-023-00-X |
Perboric acid (H3BO2(O2)), monosodium salt trihydrate |
13517-20-9
|
H360FD H332 H335 H318 |
|
Perboric acid, sodium salt, tetrahydrate |
37244-98-7
|
||
|
Perboric acid (HBO(O2)), sodium salt, tetrahydrate |
10486-00-7
|
||
|
Sodium peroxoborate, hexahydrate |
- |
||
|
005-024-00-5 |
Sodium peroxometaborate |
7632-04-4 |
H272 H360FD H331 H302 H335 H318 |
|
006-104-00-2 |
Multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T |
|
H350i H372 (lung) (inhalation) |
|
029-026-00-0 |
Copper [specific surface area > 0,67 mm2 /mg] |
7440-50-8
|
H400 H410
|
|
047-004-00-9 |
Silver massive: [particle diameter ≥ 1 mm |
7440-22-4 |
H361f H373 (nervous system) |
|
047-005-00-4 |
Silver powder: [particle diameter > 100 nm < 1 mm] |
7440-22-4 |
H361f H373 (nervous system) H400 H410 |
|
047-006-00-X |
Silver nano: [particle diameter > 1 nm ≤ 100 nm] |
7440-22-4 |
H361f H373 (nervous system) H400 H410 |
|
603-247-00-8 |
Reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol |
- |
H360Df |
|
605-042-00-9 |
α-methyl-1,3-benzodioxole-5-propionaldehyde |
1205-17-0
|
H317 |
|
(S)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2S)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal |
737776-68- 0
|
||
|
(R)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2R)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal |
737776-59- 9 |
||
|
605-043-00-4 |
2,4-dimethylcyclohex-3-ene-1-carbaldehyde |
68039-49-6 |
H317 |
|
(1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde |
35145-02-9
|
||
|
2,6-dimethylcyclohex-3-ene-1-carbaldehyde |
6975-94-6
|
||
|
3,5-dimethylcyclohex-3-ene-1-carbaldehyde |
68039-48-5
|
||
|
3,6-dimethylcyclohex-3-ene-1-carbaldehyde |
67801-65-4
|
||
|
4,6-dimethylcyclohex-3-ene-1-carbaldehyde |
36635-35-5
|
||
|
Reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde |
- |
||
|
Dimethylcyclohex-3-ene-1-carbaldehyde |
27939-60-2
|
||
|
Dimethylcyclohex-3-ene-1-carbaldehyde |
68737-61-1 |
||
|
1,2,4(or 1,3,5)-trimethyl cyclohex-3-ene-1-carbaldehyde |
71832-78-5
|
||
|
1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde |
40702-26-9
|
||
|
2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde |
1726-47-2
|
||
|
2,4,6-trimethylcyclohex-3-enecarbaldehyde |
1423-46-7
|
||
|
Isocyclocitral |
1335-66-6 |
||
|
3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde |
67634-07-5
|
||
|
4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde |
6754-27-4
|
||
|
606-156-00-1 |
Acetone oxime |
127-06-0 |
H350 H312 H336 H373 (blood system) H318 H317 |
|
606-157-00-7 |
(3E)-dec-3-en-2-one |
18402-84-1 |
H332 H304 H315 H411 |
|
606-158-00-2 |
2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one |
119344-86-4 |
H360Df H400 H410 |
|
607-770-00-2 |
2,3-epoxypropyl neodecanoate |
26761-45-5 |
H341 H317 |
|
607-771-00-8 |
Benthiavalicarb-isopropyl (ISO); isopropyl [(S)-1-{[(R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate |
177406-68-7 |
H350 H361fd H317 H411 |
|
607-772-00-3 |
Hexyl salicylate |
6259-76-3 |
H361d H317 |
|
607-773-00-9 |
7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate |
2386-87-0 |
H341 H373 (nasal cavity) H317
|
|
607-773-00-9 |
Tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphoonatooxy)ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate |
17095-24-8
|
H334 H317 |
|
Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotized 2-[(4-aminophenyl)sulfonyl]ethylhydrogen sulfate, sodium salts
|
- |
||
|
Disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate |
100556-82-9 |
||
|
607-775-00-X |
Sodium 3-(allyloxy)-2-hydroxypropanesulphonate |
52556-42-0 |
H360F H318 |
|
609-074-00-4 |
1,4-dichloro-2-nitrobenzene |
89-61-2 |
H350 |
|
611-182-00-1 |
2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol |
68516-81-4
|
H317 |
|
612-299-00-0 |
Fenpropidin (ISO); (R,S)-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine |
67306-00-7 |
H361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H400 H410 |
|
613-350-00-X |
1H-benzotriazole |
95-14-7 |
H411 |
|
613-351-00-5 |
Methyl-1H-benzotriazole |
29385-43-1 |
H411 |
|
616-243-00-6 |
N,N'-methylenediacrylamide |
110-26-9 |
H340 |
|
617-024-00-8 |
Tert-butyl 2-ethylperoxyhexanoate |
3006-82-4 |
H360FD H317 |
For full access to the regulation, visit https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L_202402564
Deadline for 21st Adaptation to Technical Progress
The previous ATP (21st ATP) was published in the Official Journal of the European Union on 5 January 2024 and will apply from 1 September 2025. It, however, entered into force on 25 January 2024 and therefore suppliers may already now classify label and package substances and mixtures in accordance with the CLP regulation as amended by the 21st ATP.
We acknowledge that the above information has been compiled from European Commission.
Global Product Compliance (GPC) specializes in Global Regulatory Compliance Solutions across sectors
globally. SSS Europe, a familiar name in chemical regulatory and compliance services now formally belongs
under the umbrella of GPC Holding Sweden.
Since 2008, we have emerged as one of the leading names among Global Regulatory Compliance Service
Providers with Representation services in Europe, Asia and Middle East for respective chemical
regulations.
